Changes in Senior Management, Exchange Transaction, Financial Results, and Public Offering of Shares - Research Report on Bristol-Myers Squibb, HealthSouth, TearLab, Synta, and Ophthotech Editor Note: For more information about this release, please scroll to bottom PR Newswire NEW YORK, November 18, 2013 NEW YORK, November 18, 2013 /PRNewswire/ -- Today, Analysts' Corner announced new research reports highlighting Bristol-Myers Squibb Company (NYSE: BMY), HealthSouth Corp. (NYSE: HLS), TearLab Corporation (NASDAQ: TEAR), Synta Pharmaceuticals Corp. (NASDAQ: SNTA), and Ophthotech Corporation (NASDAQ: OPHT). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Bristol-Myers Squibb Company Research Report On November 13, 2013, Bristol-Myers Squibb Company (Bristol-Myers Squibb) announced a series of changes within its Senior Management Team. The Company informed that it has appointed Giovanni Caforio as Executive Vice President and Chief Commercial Officer, while its Executive Vice President and CFO Charles Bancroft will hold an expanded role that includes the Business Development and Strategy groups. Besides, Murdo Gordon was appointed as the President of the Company's U.S. business. According to Bristol-Myers Squibb, it is evolving its business model, creating a global integrated commercial organization, and expanding the scope of its finance organization. The Full Research Report on Bristol-Myers Squibb Company - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.AnalystsCorner.com/r/full_research_report/81a9_BMY -- HealthSouth Corp. Research Report On November 12, 2013, HealthSouth Corp. (HealthSouth) announced that it has entered into separate, privately negotiated exchange agreements under which it will issue $320 million in aggregate principal amount of new 2.0% Convertible Senior Subordinated Notes due 2043 in exchange for 257,110 shares of the Company's outstanding 6.5% Series A Convertible Perpetual Preferred Stock, par value $0.10 per share. HealthSouth reported that the exchange transaction is expected to close on November 18, 2013, following which 96,245 shares of the preferred stock will remain outstanding. Doug Coltharp, Executive Vice President and CFO of HealthSouth, stated, "The refinancing transactions we announced today provide significant benefits to the Company and its shareholders." Coltharp added, "This transaction is immediately cash flow accretive replacing $16.7 million in cash preferred dividend payments with $6.4 million in cash interest payments, both on an annual, pre-tax basis. In addition, the transaction is not dilutive to the share count. As a result of this transaction, we expect a one-time reduction to net income attributable to HealthSouth common stockholders in the fourth quarter of 2013 of approximately $71 million, or $0.82 per basic share, as the repurchase premium over the book value of the preferred stock being exchanged will be accounted for similar to a preferred dividend payment." The Full Research Report on HealthSouth Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.AnalystsCorner.com/r/full_research_report/9080_HLS -- TearLab Corporation Research Report On November 12, 2013, TearLab Corporation (TearLab) released its Q3 2013 results. TearLab registered revenues of $4.2 million in Q3 2013, up 247.4% YoY. The Company posted net loss of $4.2 million in Q3 2013, compared to net loss of $4.6 million in Q3 2012. TearLab reported basic and diluted loss per share of $0.13 in Q3 2013, compared to that of $0.17 in Q3 2012. Elias Vamvakas, TearLab's CEO, commented, "Awareness and use of the TearLab Osmolarity test continued to build in the third quarter, as demonstrated by our strong system order volumes and revenue growth in what is historically a seasonally weaker period in the eye care industry." The Full Research Report on TearLab Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.AnalystsCorner.com/r/full_research_report/58d3_TEAR -- Synta Pharmaceuticals Corp. Research Report On November 13, 2013, Synta Pharmaceuticals Corp. (Synta) announced that it has priced an underwritten public offering of 14.0 million shares of its common stock at a price to the public of $3.75 per share. According to Synta, it has granted the underwriters a 30-day option to purchase up to 2.1 million additional shares. Synta reported that the offering is expected to close on or about November 18, 2013, subject to satisfaction of customary closing conditions and is expected to generate a gross proceeds of c.$52.5 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by the Company. The Full Research Report on Synta Pharmaceuticals Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.AnalystsCorner.com/r/full_research_report/8ecc_SNTA -- Ophthotech Corporation Research Report On November 13, 2013, Ophthotech Corporation (Ophthotech) released its Q3 2013 results. Ophthotech registered net loss attributable to common shareholders of $18.4 million in Q3 2013, compared to net loss attributable to common shareholders of $5.9 million in Q3 2012. The Company posted basic and diluted net loss per share attributable to common shareholders of $10.26 in Q3 2013, compared to basic and diluted net loss per share attributable to common shareholders of $4.07 in Q3 2012. David Guyer, M.D., CEO of Ophthotech, said, "It has been a productive and exciting time for Ophthotech as we expanded our management team and completed our IPO, which was one of the largest for the sector this year." Guyer added, "We have made meaningful progress in our clinical programs including advancing FovistaTM into Phase 3 pivotal trials and greatly expanded our financial resources to allow us to continue our development efforts." The Full Research Report on Ophthotech Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.AnalystsCorner.com/r/full_research_report/91ff_OPHT ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. SOURCE Analysts' Corner Contact: CONTACT PERSON: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North America)
Changes in Senior Management, Exchange Transaction, Financial Results, and Public Offering of Shares - Research Report on
Press spacebar to pause and continue. Press esc to stop.